Efficacy and Safety of the Combination of Rucaparib (PARP Inhibitor) and Atezolizumab (Anti-PD-L1 Antibody) in Patients With DNA Repair-deficient or Platinum-sensitive Solid Tumors
Clinical trial NCT04276376 · TERMINATED
Trial details
- NCT number
- NCT04276376
- Sponsor
- Gustave Roussy, Cancer Campus, Grand Paris
- Status
- TERMINATED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2019-04-12
- Primary completion
- 2023-01-25
- Enrollment
- 130
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.